Products RotaTeq™ (V260) + DTP-IPV
RotaTeq™ (V260) + DTP-IPV Approved Completed ⚡ Active Interest: 43/100
Sep 19, 2013 → Jun 6, 2014
About RotaTeq™ (V260) + DTP-IPV RotaTeq™ (V260) + DTP-IPV is a approved stage product being developed by Merck for Rotavirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01926015. Target conditions include Rotavirus Disease.
What happened to similar drugs? 0 of 12 similar drugs in Rotavirus Disease were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01926015 Approved Completed Sep 19, 2013 Jun 6, 2014 Rotavirus Disease
Product Company Stage Hype Score Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™ Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered) Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 Rotateq™ + Comparator: Placebo Merck Phase 3 Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 rotavirus vaccine, live, oral, pentavalent + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa Merck Phase 3 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 Rotarix + RotaTeq Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) Merck Phase 3